Workflow
Pluri Announces Expansion of Intellectual Property Portfolio with Two Granted Patents for 3D Expansion of Immune Cells in the United States and Israel
PLURPluri (PLUR) Newsfilter·2025-04-10 20:30

Latest granted patents reinforce Pluri's position as a leader in Mucosal-Associated Invariant T ("MAIT") cell-based cell therapies for solid cancersPluri's MAIT platform enables commercial scale production of powerful immune cells as a potential first-in-class, ready to use, "off-the-shelf" therapy for cancer patientsPluri's MAIT platform addresses the global immune cell engineering market, projected to reach approximately 11.7billionby2030,andtheglobalcancerimmunotherapymarket,calculatedat11.7 billion by 2030, and the global cancer immunotherapy market, calculated at 136 ...